Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy
Recurrent glioblastomas (rGBM) have dismal outcomes, but long-term survival has been observed in subsets of patients after immunotherapy. Here the authors report a positive association between low tumor mutation burden, inflammatory gene signatures, and survival after immunotherapy in rGBM patients.
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2021-01-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-020-20469-6 |
| id |
doaj-9b4f7304b8f54613b5f0b6626698e589 |
|---|---|
| record_format |
Article |
| spelling |
doaj-9b4f7304b8f54613b5f0b6626698e5892021-01-17T12:12:04ZengNature Publishing GroupNature Communications2041-17232021-01-011211710.1038/s41467-020-20469-6Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapyMatthias Gromeier0Michael C. Brown1Gao Zhang2Xiang Lin3Yeqing Chen4Zhi Wei5Nike Beaubier6Hai Yan7Yiping He8Annick Desjardins9James E. Herndon10Frederick S. Varn11Roel G. Verhaak12Junfei Zhao13Dani P. Bolognesi14Allan H. Friedman15Henry S. Friedman16Frances McSherry17Andrea M. Muscat18Eric S. Lipp19Smita K. Nair20Mustafa Khasraw21Katherine B. Peters22Dina Randazzo23John H. Sampson24Roger E. McLendon25Darell D. Bigner26David M. Ashley27Department of Neurosurgery, Duke University Medical CenterDepartment of Neurosurgery, Duke University Medical CenterDepartment of Neurosurgery, Duke University Medical CenterDepartment of Computer Science at the New Jersey Institute of TechnologyDepartment of Computer Science at the New Jersey Institute of TechnologyDepartment of Computer Science at the New Jersey Institute of TechnologyTempus Labs, Inc.The Preston Robert Tisch Brain Tumor Center at Duke University Medical CenterThe Preston Robert Tisch Brain Tumor Center at Duke University Medical CenterDepartment of Neurosurgery, Duke University Medical CenterThe Preston Robert Tisch Brain Tumor Center at Duke University Medical CenterThe Jackson Laboratory for Genomic MedicineThe Jackson Laboratory for Genomic MedicineDepartment of Systems Biology at Columbia UniversityDepartment of Surgery, Duke University Medical CenterDepartment of Neurosurgery, Duke University Medical CenterDepartment of Neurosurgery, Duke University Medical CenterDepartment of Biostatistics, Duke University Medical CenterSchool of Medicine, Deakin UniversityDepartment of Neurosurgery, Duke University Medical CenterDepartment of Surgery, Duke University Medical CenterDepartment of Neurosurgery, Duke University Medical CenterDepartment of Neurosurgery, Duke University Medical CenterDepartment of Neurosurgery, Duke University Medical CenterDepartment of Neurosurgery, Duke University Medical CenterThe Preston Robert Tisch Brain Tumor Center at Duke University Medical CenterDepartment of Neurosurgery, Duke University Medical CenterDepartment of Neurosurgery, Duke University Medical CenterRecurrent glioblastomas (rGBM) have dismal outcomes, but long-term survival has been observed in subsets of patients after immunotherapy. Here the authors report a positive association between low tumor mutation burden, inflammatory gene signatures, and survival after immunotherapy in rGBM patients.https://doi.org/10.1038/s41467-020-20469-6 |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Matthias Gromeier Michael C. Brown Gao Zhang Xiang Lin Yeqing Chen Zhi Wei Nike Beaubier Hai Yan Yiping He Annick Desjardins James E. Herndon Frederick S. Varn Roel G. Verhaak Junfei Zhao Dani P. Bolognesi Allan H. Friedman Henry S. Friedman Frances McSherry Andrea M. Muscat Eric S. Lipp Smita K. Nair Mustafa Khasraw Katherine B. Peters Dina Randazzo John H. Sampson Roger E. McLendon Darell D. Bigner David M. Ashley |
| spellingShingle |
Matthias Gromeier Michael C. Brown Gao Zhang Xiang Lin Yeqing Chen Zhi Wei Nike Beaubier Hai Yan Yiping He Annick Desjardins James E. Herndon Frederick S. Varn Roel G. Verhaak Junfei Zhao Dani P. Bolognesi Allan H. Friedman Henry S. Friedman Frances McSherry Andrea M. Muscat Eric S. Lipp Smita K. Nair Mustafa Khasraw Katherine B. Peters Dina Randazzo John H. Sampson Roger E. McLendon Darell D. Bigner David M. Ashley Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy Nature Communications |
| author_facet |
Matthias Gromeier Michael C. Brown Gao Zhang Xiang Lin Yeqing Chen Zhi Wei Nike Beaubier Hai Yan Yiping He Annick Desjardins James E. Herndon Frederick S. Varn Roel G. Verhaak Junfei Zhao Dani P. Bolognesi Allan H. Friedman Henry S. Friedman Frances McSherry Andrea M. Muscat Eric S. Lipp Smita K. Nair Mustafa Khasraw Katherine B. Peters Dina Randazzo John H. Sampson Roger E. McLendon Darell D. Bigner David M. Ashley |
| author_sort |
Matthias Gromeier |
| title |
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy |
| title_short |
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy |
| title_full |
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy |
| title_fullStr |
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy |
| title_full_unstemmed |
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy |
| title_sort |
very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy |
| publisher |
Nature Publishing Group |
| series |
Nature Communications |
| issn |
2041-1723 |
| publishDate |
2021-01-01 |
| description |
Recurrent glioblastomas (rGBM) have dismal outcomes, but long-term survival has been observed in subsets of patients after immunotherapy. Here the authors report a positive association between low tumor mutation burden, inflammatory gene signatures, and survival after immunotherapy in rGBM patients. |
| url |
https://doi.org/10.1038/s41467-020-20469-6 |
| work_keys_str_mv |
AT matthiasgromeier verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT michaelcbrown verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT gaozhang verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT xianglin verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT yeqingchen verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT zhiwei verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT nikebeaubier verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT haiyan verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT yipinghe verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT annickdesjardins verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT jameseherndon verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT fredericksvarn verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT roelgverhaak verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT junfeizhao verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT danipbolognesi verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT allanhfriedman verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT henrysfriedman verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT francesmcsherry verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT andreammuscat verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT ericslipp verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT smitaknair verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT mustafakhasraw verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT katherinebpeters verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT dinarandazzo verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT johnhsampson verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT rogeremclendon verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT darelldbigner verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy AT davidmashley verylowmutationburdenisafeatureofinflamedrecurrentglioblastomasresponsivetocancerimmunotherapy |
| _version_ |
1724335277597523968 |